These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. ICON2 trial. UK consensus statement on standard practice for chemotherapy in ovarian cancer. Gore ME Lancet; 1999 Feb; 353(9152):587-8. PubMed ID: 10029003 [No Abstract] [Full Text] [Related]
3. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
4. The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111). Swart AM; Parmar MK; Harper P; Colombo N; Torri V Int J Gynecol Cancer; 2004; 14(4):697; author reply 698. PubMed ID: 15304171 [No Abstract] [Full Text] [Related]
5. Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Atkins CD J Natl Cancer Inst; 2000 Sep; 92(17):1446-7. PubMed ID: 10974091 [No Abstract] [Full Text] [Related]
6. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Sandercock J; Parmar MK; Torri V Br J Cancer; 1998 Dec; 78(11):1471-8. PubMed ID: 9836480 [TBL] [Abstract][Full Text] [Related]
7. Platinum alone for chemotherapy for ovarian cancer? Johnston C Lancet; 1998 Nov; 352(9140):1567-8. PubMed ID: 9843097 [No Abstract] [Full Text] [Related]
8. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]
9. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide? Sugiyama T Int J Clin Oncol; 2006 Jun; 11(3):163. PubMed ID: 16850120 [No Abstract] [Full Text] [Related]
10. Carboplatin versus cisplatin in ovarian cancer. Alberts DS Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869 [TBL] [Abstract][Full Text] [Related]
11. ICON3 and chemotherapy for ovarian cancer. Ozols RF; Markman M; Thigpen JT Lancet; 2002 Dec 21-28; 360(9350):2086-7; author reply 2088. PubMed ID: 12504453 [No Abstract] [Full Text] [Related]
12. [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study]. Richter P; Krafft W; Müller U; Brückmann D; Homann S; König EM; Lotze P; Morack G; Neubert S; Nöschel H Zentralbl Gynakol; 1990; 112(7):421-9. PubMed ID: 1695049 [TBL] [Abstract][Full Text] [Related]
13. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106 [TBL] [Abstract][Full Text] [Related]
14. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101 [TBL] [Abstract][Full Text] [Related]
15. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. Buyse M; Burzykowski T; Parmar M; Torri V; Omura G; Colombo N; Williams C; Conte P; Vermorken J; ; J Clin Oncol; 2003 May; 21(9):1682-7. PubMed ID: 12721242 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for ovarian cancer--a consensus statement on standard practice. Adams M; Calvert AH; Carmichael J; Clark PI; Coleman RE; Earl HM; Gallagher CJ; Ganesan TS; Gore ME; Graham JD; Harper PG; Jayson GC; Kaye SB; Ledermann JA; Osborne RJ; Perren TJ; Poole CJ; Radford JA; Rustin GJ; Slevin ML; Smyth JF; Thomas H; Wilkinson PM Br J Cancer; 1998 Dec; 78(11):1404-6. PubMed ID: 9836470 [No Abstract] [Full Text] [Related]
17. Good manners for the pharmaceutical industry. Gore M; A'Hern R; Swenerton K Lancet; 1997 Aug; 350(9074):370. PubMed ID: 9251668 [No Abstract] [Full Text] [Related]